TP53, BCL-2, p21Waf1/Cip1 and metallothionein as markers of differentiation, response to treatment and prognosis in neuroblastic tumors

Analytical and Quantitative Cytology and Histology

Volumn 30, Issue 2, 2008, Pages 105-112

  Lara Bohórquez, Concepción ^a   González Cámpora, Ricardo ^b   Mendoza García, Eladio ^c   Ríos Martín, Juan José ^b   Pareja Megía, María Jesús ^d   López Beltrán, Antonio ^d  

^a HOSPITAL INFANTA ELENA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

BCL 2; Maturation; Metallothionein; Neuroblasts tumors; p21Waf1 Cip1; Prognosis; TP53

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 1; KI 67 ANTIGEN; METALLOTHIONEIN; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CAUSE OF DEATH; CELL DIFFERENTIATION; CHILD; FEMALE; GANGLIONEUROMA; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NEUROSURGERY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CELL DIFFERENTIATION; CHILD; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GANGLIONEUROBLASTOMA; HUMANS; MALE; METALLOTHIONEIN; NEUROBLASTOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 41849091539     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Lopez-Beltran A, MacLennan GT, De la Haba-Rodriguez J, Montironi R, Cheng L: Research advances in apoptosis-mediated cancer therapy: A review. Anal Quant Cytol Histol 2007;29:71-78
2. Ikeda H, Hirato J, Akami M, Matsuyama S, Suzuki N, Takahashi A, Kuroiwa M: Bcl-2 oncoprotein expression and apoptosis in neuroblastoma. J Pediatr Surg 1995;30:805-808
3. Koizumi H, Wakisaka M, Nakada K, Takakuwa T, Fujioka T, Yamate N, Uchikoshi T: Demonstration of apoptosis in neuroblastoma and its relationship to tumor regression. Virchows Arch 1995;427:167-173
4. Beierle EA, Dai W, Iyengar R, Langham MR Jr, Copeland EM 3rd, Chen MK: Differential expression of Bcl-2 and Bax may enhance neuroblastoma survival. J Pediatr Surg 2003;38:486-491
5. Uccini S, Colarossi C, Scarpino S, Boldrini R, Natali PG, Nicotra MR, Perla FM, Mannarino O, Altavista P, Boglino C, Cappelli CA, Cozzi D, Donfrancesco A, Kokai G, Losty PD, McDowell HP, Dominici C: Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblasts tumors. Br J Cancer 2006;95:49-55
6. Ribas J, Boix J: Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs. Exp Cell Res 2004;295:9-24
7. Rocchi P, Tonelli R, Camerin C, Purgato S, Fronza R, Bianucci F, Guerra F, Pession A, Ferreri AM: p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep 2005;13:1139-1144
8. Gallo G, Giarnieri E, Bosco S, Cappelli C, Alderisio M, Giovagnoli MR, Giordano A, Vecchione A: Aberrant bcl-2 and bax protein expression related to chemotherapy response in neuroblastoma. Anticancer Res 2003;23:777-784
9. Niizuma H, Nakamura Y, Ozaki T, Nakanishi H, Ohira M, Isogai E, Kageyama H, Imaizumi M, Nakagawara A: Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma. Oncogene 2006;25:5046-5055
10. Jasani B, Edwards M, Vujanic G: Infrequent over-expression of metallothionein (MT) in pediatric tumors and its posible significance. J Pathol 1997;181:38A
11. Moll UM, LaQuaglia M, Bérnard J, Riou G: Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 1995;92:4407-4411
12. Kleihues P, Cavenee WK: World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Nervous System. Lyon, IARC Press, 2000, pp 153-161
13. Mejia MC, Navarro S, Pellin A, Castel V, Llombart-Bosch A: Study of bcl-2 protein expression and the apoptosis phenomenon in neuroblastoma. Anticancer Res 1998;18:801-806
14. Vogan K, Bernstein M, Leclerc M, Brisson L, Brossard J, Brodeur GM, Pelletier J, Gros P: Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 1993;53:5269-5273
15. Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C, Lunec J: The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 2003;197:93-98
16. Carr J, Bell E, Pearson AD, Kees UR, Beris H, Lunec J, Tweddle DA: Increased frequency of aberrations in the p53/MDM2/p14 (ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res 2006;66:2138-2145
17. McKenzie PP, Danks MK, Kriwacki RW, Harris LC: P21P21/Cip1 dysfunction in neuroblastoma: A novel mechanism of attenuating G0.G1 cell cycle arrest. Cancer Res 2003;63:3840-3844
18. Weinberg RA: The Biology of Cancer. New York, Garland Science, 2007, pp 307-356
19. Vázquez-Ramírez FJ, González-Cámpora JJ, Hevia-Alvarez E, Fernández-Santos JM, Ríos-Martín JJ, Otal-Salaverri C, González-Cámpora R: P-glycoprotein, metallothionein and NM23 protein expressions in breast carcinoma. Pathol Res Pract 2000;196:553-559
20. Riley RD, Heney D, Jonnes DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ, Burchill SA: A systematic review of molecular and biological tumors markers in neuroblastoma. Clin Cancer Res 2004;10:4-12
21. Tweddle DA, Malcolm AJ, Cole M, Pearson ADJ, Lunec J: p53 cellular localization and function in neuroblastoma: Evidence for defective G1 arrest despite p21 induction in MYCN-amplified cells. Am J Pathol 2001;158:2067-2077
22. Nikolaev AY, Li M, Puskas N, Qin J, Gu W: Parc: A cytoplasmic anchor for p53. Cell 2003;112:29-40
23. Lopez-Beltran A, MacLennan GT, Montironi R: Cyclin E as molecular marker in the management of breast cancer: A review. Anal Quant Cytol Histol 2006;28:111-114
24. Schwab M: MYC-N in neuronal tumors. Cancer Lett 2004; 204:179-187
25. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM: The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA 2005;102:731-736
26. Lazo JS, Pitt BR: Metallothioneins and cell death by anticancer drugs. Annu Rev Pharmacol Toxicol 1995;35:635-653
27. Yasuno T, Matsumura T, Shikata T, Inazawa J, Sakabe T, Tsuchida S, Takahata T, Miyairi S, Naganuma A, Sawada T: Establishment and characterization of a cisplatin-resistant human neuroblastoma cell line. Anticancer Res 1999;19:4049-4057